Kineta Income from Continuous Operations 2014-2024 | KANT
Kineta income from continuous operations from 2014 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Kineta Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-14 |
| 2022 |
$-63 |
| 2021 |
$-12 |
| 2020 |
$-57 |
| 2019 |
$-31 |
| 2018 |
$-62 |
| 2017 |
$-59 |
| 2016 |
$-37 |
| 2015 |
$-25 |
| 2014 |
$-16 |
| 2013 |
$-16 |
Kineta Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$-3 |
| 2024-03-31 |
$-10 |
| 2023-12-31 |
$-3 |
| 2023-09-30 |
$-5 |
| 2023-06-30 |
$0 |
| 2023-03-31 |
$-6 |
| 2022-12-31 |
$-47 |
| 2022-09-30 |
$-6 |
| 2022-06-30 |
$-6 |
| 2022-03-31 |
$-5 |
| 2021-12-31 |
$17 |
| 2021-09-30 |
$-10 |
| 2021-06-30 |
$-10 |
| 2021-03-31 |
$-9 |
| 2020-12-31 |
$-37 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$16 |
| 2019-09-30 |
$-13 |
| 2019-06-30 |
$-20 |
| 2019-03-31 |
$-14 |
| 2018-12-31 |
$-17 |
| 2018-09-30 |
$-18 |
| 2018-06-30 |
$-15 |
| 2018-03-31 |
$-11 |
| 2017-12-31 |
$-13 |
| 2017-09-30 |
$-14 |
| 2017-06-30 |
$-17 |
| 2017-03-31 |
$-15 |
| 2016-12-31 |
$-9 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-8 |
| 2015-12-31 |
$-6 |
| 2015-09-30 |
$-7 |
| 2015-06-30 |
$-7 |
| 2015-03-31 |
$-6 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
